Help patients get the answers they need.

Serology tests may miss
patients who had COVID-19.
T cells have the answer.

Help patients get the answers they need.

Serology tests may miss
patients who had COVID-19.
T cells have the answer.

T-Detect COVID is authorized under the FDA Emergency Use Authorization (EUA).*

T cells vs. antibodies

T-Detect COVID is a highly sensitive and specific test that can detect the specific T-cell signature in response to SARS-CoV-2, the virus that causes COVID-19.

In studies, T-cell testing performed as well as or better than leading antibody tests.1, 2


Physicians Data Sensitivity


Physicians Data Specificity

Specificity was based on negative percent agreement (NPA) in pre-pandemic controls and RT-PCR negative subjects.

T Detect Physician Action

Learn more

Read the T-Detect COVID physician brochure.



Physician Brochure

How it works

Account Set Up

1. Partner

Sign a business agreement, establish an account and prepay for test kits. Contact us to learn more.


2. Blood draw

Place a patient order, collect the blood sample and ship the kit back to Adaptive Biotechnologies.


3. Results

Receive results via our secure portal approximately 7-10 days from shipment of blood sample (including 5-7 days for lab processing*).

* Lab processing begins once all required provider and patient information is validated.


  1. Dalai, S, et al. Clinical Validation of a Novel T-Cell Receptor Sequencing Assay for Identification of Recent or Prior SARS-CoV-2 Infection. medRxiv. 2021.
  2. Elyanow R., et al. T-cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibody titers and disease severity. medRxiv. 2021.
  3. Data on file. Adaptive Biotechnologies. 2021.

T-Detect™ COVID is not FDA cleared or approved. It is authorized for emergency use under an Emergency Use Authorization (EUA). 

Testing of venous whole blood using K2 EDTA specimens is limited to laboratories designated by Adaptive Biotechnologies Corporation that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meets the requirements to perform high complexity tests as described in the T-Detect COVID Test Standard Operating Procedure that was reviewed by the FDA under this EUA.

This test has been authorized only for detecting and identifying the presence of an adaptive T-cell immune response to SARS-CoV-2, not for any other viruses or pathogens.

The performance of this test was established based on the evaluation of a limited number of clinical specimens. Clinical performance has not been established with all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARS-CoV-2 and their prevalence, which change over time.  

The emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

T-Detect™ COVID is not indicated for use in patients under age 18.